Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Guardant Health, Inc. GH

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$982.0M
▲ 32.9% YoY
$-416.3M
$-233.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Guardant Health, Inc. provides tests that span all stages of cancer care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For early cancer detection, it offers the Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease. It performs clinical, research-use-only, and investigation-use-only tests in laboratories located in Redwood City, California, and Long Island City, New York, with its Redwood City, San Diego and Palo Alto, California laboratories also operating as centers for research and technology development. As of December 31, 2025, it had 2,506 employees, 2,490 of which are full-time, with approximately 2,278 in the U.S. and the remainder in Asia, Europe and Canada.

Written from the business description in GUARDANT HEALTH, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth

USD 982.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 982.0 · Net income -416.3
400.0M800.0M-250.0M-500.0M
2017202020232025
Compound annual growth
+29.8%
+27.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +27.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−42 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -44.5% · Net -42.4%
-50%-100%-150%
201720212025
ROE
FY2023 · ROE -438.1%
-200%-400%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -29%.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -233.1
-150M-300M
201720212025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks -212.1
-200M-400M
2017201820192020202320242025

Total assetsUSD 2.0B
EquityUSD -99.3M
CashUSD 378.2M
Gross debtUSD 1.5B
Net debtUSD 1.1B
Current ratio4.84×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GH, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B1.00.70.60.40.40.30.20.10.0
Operating income $B−0.4−0.4−0.6−0.5−0.4−0.3−0.1−0.1−0.1
EBITDA $B−0.4−0.4−0.5−0.5−0.4−0.2−0.1−0.1−0.1
Income tax $B−0.00.00.00.00.00.0−0.00.00.0
Net income $B−0.4−0.4−0.5−0.7−0.4−0.2−0.1−0.1−0.1
Free cash flow $B−0.2−0.3−0.3−0.4−0.3−0.1−0.1−0.1−0.1
EPS, diluted $−3.32−3.56−4.28−6.41−4.00−2.60−0.84−2.80−7.07
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %——−438.1−185.7−39.6◌−11.8−21.5−27.0
Shares out B0.130.120.120.100.100.100.090.09◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 16 checks were skipped: cost of revenue is not tagged before 2023. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image